Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients

R. Fossati, C. Confalonieri, G. Apolone, A. Nicolucci, G. Tognoni, W. Torri, A. Liberati, P. Gosso, D. Tagliati, F. Di Vito, F. Grasso, P. A. Nannicini, M. Rinaldini, G. Di Biagio, M. Belli, G. Colantuoni, T. Pedicini, R. Vincenti, M. Fumagalli, G. Gritti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Indications for and modes of delivery of adjuvant chemotherapy in early breast cancer were assessed in a group of 353 patients followed within a cohort of 1110 newly diagnosed cases in 54 Italian general hospitals. Among node-positive patients 79% pre- and 44% post-menopausal women had the treatment. Only a few node-negative women (10% pre- and 5% post-menopausal) were treated. The multidrug combination CMF was by far the most commonly employed (89%) in its two types: cCMF (the classic combination where cyclophosphamide is given orally on days 1-14 and the two other drugs i.v. on days 1 and 8 every 28 days for either 6 or 12 cycles) to 33% women and nCMF (the more recent combination where all three drugs are given i.v. on day 1 every 21 days for 12 cycles) to 63%. The mode of delivery of treatment was consistent with the Italian National Breast Cancer Task Force (F.O.N.Ca.M.) recommendations for the cCMF combination, but the lack of clear guidelines on the use of nCMF led to wide variations in the total number of cycles administered. At present, however, it is hard to establish whether this will have any impact on patients' outcome. Overall the study suggests that adjuvant chemotherapy for breast cancer has entered general practice and can be satisfactory delivered at the community level. However, better guidelines need to specify more precisely the treatment indications (i.e. subgroups with greater expected benefits), regimen type (is nCMF still experimental or already standard?) and treatment duration in view of the present uncertainty about what should be the standard for general practice. The paper finally discusses the feasibility of the treatment comparing general hospitals' performance with that achieved in controlled clinical trials of adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)377-386
Number of pages10
JournalTumori
Volume74
Issue number4
Publication statusPublished - 1988

Fingerprint

Adjuvant Chemotherapy
General Hospitals
Breast Neoplasms
General Practice
Guidelines
Therapeutics
Controlled Clinical Trials
Advisory Committees
Pharmaceutical Preparations
Cyclophosphamide
Uncertainty

ASJC Scopus subject areas

  • Cancer Research

Cite this

Fossati, R., Confalonieri, C., Apolone, G., Nicolucci, A., Tognoni, G., Torri, W., ... Gritti, G. (1988). Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients. Tumori, 74(4), 377-386.

Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients. / Fossati, R.; Confalonieri, C.; Apolone, G.; Nicolucci, A.; Tognoni, G.; Torri, W.; Liberati, A.; Gosso, P.; Tagliati, D.; Di Vito, F.; Grasso, F.; Nannicini, P. A.; Rinaldini, M.; Di Biagio, G.; Belli, M.; Colantuoni, G.; Pedicini, T.; Vincenti, R.; Fumagalli, M.; Gritti, G.

In: Tumori, Vol. 74, No. 4, 1988, p. 377-386.

Research output: Contribution to journalArticle

Fossati, R, Confalonieri, C, Apolone, G, Nicolucci, A, Tognoni, G, Torri, W, Liberati, A, Gosso, P, Tagliati, D, Di Vito, F, Grasso, F, Nannicini, PA, Rinaldini, M, Di Biagio, G, Belli, M, Colantuoni, G, Pedicini, T, Vincenti, R, Fumagalli, M & Gritti, G 1988, 'Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients', Tumori, vol. 74, no. 4, pp. 377-386.
Fossati R, Confalonieri C, Apolone G, Nicolucci A, Tognoni G, Torri W et al. Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients. Tumori. 1988;74(4):377-386.
Fossati, R. ; Confalonieri, C. ; Apolone, G. ; Nicolucci, A. ; Tognoni, G. ; Torri, W. ; Liberati, A. ; Gosso, P. ; Tagliati, D. ; Di Vito, F. ; Grasso, F. ; Nannicini, P. A. ; Rinaldini, M. ; Di Biagio, G. ; Belli, M. ; Colantuoni, G. ; Pedicini, T. ; Vincenti, R. ; Fumagalli, M. ; Gritti, G. / Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients. In: Tumori. 1988 ; Vol. 74, No. 4. pp. 377-386.
@article{7928156c8f264983a0ddb1a6ad45215f,
title = "Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients",
abstract = "Indications for and modes of delivery of adjuvant chemotherapy in early breast cancer were assessed in a group of 353 patients followed within a cohort of 1110 newly diagnosed cases in 54 Italian general hospitals. Among node-positive patients 79{\%} pre- and 44{\%} post-menopausal women had the treatment. Only a few node-negative women (10{\%} pre- and 5{\%} post-menopausal) were treated. The multidrug combination CMF was by far the most commonly employed (89{\%}) in its two types: cCMF (the classic combination where cyclophosphamide is given orally on days 1-14 and the two other drugs i.v. on days 1 and 8 every 28 days for either 6 or 12 cycles) to 33{\%} women and nCMF (the more recent combination where all three drugs are given i.v. on day 1 every 21 days for 12 cycles) to 63{\%}. The mode of delivery of treatment was consistent with the Italian National Breast Cancer Task Force (F.O.N.Ca.M.) recommendations for the cCMF combination, but the lack of clear guidelines on the use of nCMF led to wide variations in the total number of cycles administered. At present, however, it is hard to establish whether this will have any impact on patients' outcome. Overall the study suggests that adjuvant chemotherapy for breast cancer has entered general practice and can be satisfactory delivered at the community level. However, better guidelines need to specify more precisely the treatment indications (i.e. subgroups with greater expected benefits), regimen type (is nCMF still experimental or already standard?) and treatment duration in view of the present uncertainty about what should be the standard for general practice. The paper finally discusses the feasibility of the treatment comparing general hospitals' performance with that achieved in controlled clinical trials of adjuvant chemotherapy.",
author = "R. Fossati and C. Confalonieri and G. Apolone and A. Nicolucci and G. Tognoni and W. Torri and A. Liberati and P. Gosso and D. Tagliati and {Di Vito}, F. and F. Grasso and Nannicini, {P. A.} and M. Rinaldini and {Di Biagio}, G. and M. Belli and G. Colantuoni and T. Pedicini and R. Vincenti and M. Fumagalli and G. Gritti",
year = "1988",
language = "English",
volume = "74",
pages = "377--386",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients

AU - Fossati, R.

AU - Confalonieri, C.

AU - Apolone, G.

AU - Nicolucci, A.

AU - Tognoni, G.

AU - Torri, W.

AU - Liberati, A.

AU - Gosso, P.

AU - Tagliati, D.

AU - Di Vito, F.

AU - Grasso, F.

AU - Nannicini, P. A.

AU - Rinaldini, M.

AU - Di Biagio, G.

AU - Belli, M.

AU - Colantuoni, G.

AU - Pedicini, T.

AU - Vincenti, R.

AU - Fumagalli, M.

AU - Gritti, G.

PY - 1988

Y1 - 1988

N2 - Indications for and modes of delivery of adjuvant chemotherapy in early breast cancer were assessed in a group of 353 patients followed within a cohort of 1110 newly diagnosed cases in 54 Italian general hospitals. Among node-positive patients 79% pre- and 44% post-menopausal women had the treatment. Only a few node-negative women (10% pre- and 5% post-menopausal) were treated. The multidrug combination CMF was by far the most commonly employed (89%) in its two types: cCMF (the classic combination where cyclophosphamide is given orally on days 1-14 and the two other drugs i.v. on days 1 and 8 every 28 days for either 6 or 12 cycles) to 33% women and nCMF (the more recent combination where all three drugs are given i.v. on day 1 every 21 days for 12 cycles) to 63%. The mode of delivery of treatment was consistent with the Italian National Breast Cancer Task Force (F.O.N.Ca.M.) recommendations for the cCMF combination, but the lack of clear guidelines on the use of nCMF led to wide variations in the total number of cycles administered. At present, however, it is hard to establish whether this will have any impact on patients' outcome. Overall the study suggests that adjuvant chemotherapy for breast cancer has entered general practice and can be satisfactory delivered at the community level. However, better guidelines need to specify more precisely the treatment indications (i.e. subgroups with greater expected benefits), regimen type (is nCMF still experimental or already standard?) and treatment duration in view of the present uncertainty about what should be the standard for general practice. The paper finally discusses the feasibility of the treatment comparing general hospitals' performance with that achieved in controlled clinical trials of adjuvant chemotherapy.

AB - Indications for and modes of delivery of adjuvant chemotherapy in early breast cancer were assessed in a group of 353 patients followed within a cohort of 1110 newly diagnosed cases in 54 Italian general hospitals. Among node-positive patients 79% pre- and 44% post-menopausal women had the treatment. Only a few node-negative women (10% pre- and 5% post-menopausal) were treated. The multidrug combination CMF was by far the most commonly employed (89%) in its two types: cCMF (the classic combination where cyclophosphamide is given orally on days 1-14 and the two other drugs i.v. on days 1 and 8 every 28 days for either 6 or 12 cycles) to 33% women and nCMF (the more recent combination where all three drugs are given i.v. on day 1 every 21 days for 12 cycles) to 63%. The mode of delivery of treatment was consistent with the Italian National Breast Cancer Task Force (F.O.N.Ca.M.) recommendations for the cCMF combination, but the lack of clear guidelines on the use of nCMF led to wide variations in the total number of cycles administered. At present, however, it is hard to establish whether this will have any impact on patients' outcome. Overall the study suggests that adjuvant chemotherapy for breast cancer has entered general practice and can be satisfactory delivered at the community level. However, better guidelines need to specify more precisely the treatment indications (i.e. subgroups with greater expected benefits), regimen type (is nCMF still experimental or already standard?) and treatment duration in view of the present uncertainty about what should be the standard for general practice. The paper finally discusses the feasibility of the treatment comparing general hospitals' performance with that achieved in controlled clinical trials of adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023726765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023726765&partnerID=8YFLogxK

M3 - Article

C2 - 3055576

AN - SCOPUS:0023726765

VL - 74

SP - 377

EP - 386

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -